Indication
Progressive or Recurrent Grade II or III Meningioma
1 clinical trial
1 product
Clinical trial
An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade MeningiomaStatus: Recruiting, Estimated PCD: 2025-09-30
Product
NEO100